Revenue segments as reported by the company.

Transcatheter Aortic Valve Replacement

Transcatheter Mitral and Tricuspid Therapies

Surgical Structural Heart

Critical Care

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative expenses

Research and development expenses

Intellectual property litigation expenses, net

Change in fair value of contingent consideration liabilities

Special charges

Restructuring expenses

Other operating expenses, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Edwards Lifesciences projects robust sales growth amidst market advancements

Edwards Lifesciences showcased strong sales growth and financial performance in Q4 2022. Despite challenges like FX impacts and spotty backlog, the company remains confident in its growth outlook. Encouraging opportunities lie in TMTT and Surgical Structural Heart segments for future expansion.

Edwards Lifesciences reports robust Q1 sales, eyes global expansion

Edwards Lifesciences delivered strong sales performance in Q1, driven by key product segments and global growth.
The company faces challenges in managing expenses and navigating competitive dynamics, particularly in Japan.
Opportunities lie in continued market growth, product innovation, and efficiency enhancements across operations.
Overall, Edwards Lifesciences remains well-positioned for growth and market leadership in the cardiovascular space.

Edwards Lifesciences exceeds Q2 expectations, raises full-year guidance

Edwards Lifesciences delivered strong Q2 results, raising full year guidance and highlighting growth in key segments. While facing challenges like seasonal impacts and market recovery issues, the company remains focused on innovation and market expansion.

Edwards Lifesciences excels in Q3, poised for diversified growth

Edwards Lifesciences delivered a strong Q3 performance with growth across key segments and a positive outlook for 2023.
The company's focus on innovation, differentiated sales strategies, and patient-centric initiatives position it well for future growth.
Challenges in pricing dynamics and market competition require strategic management, while opportunities in diverse therapies and patient activation initiatives offer avenues for expansion.
Overall, Edwards Lifesciences maintains a solid financial position, supported by a robust balance sheet and a commitment to long-term growth.

Edwards Lifesciences posts strong Q4 results, eyes global growth opportunities

Edwards Lifesciences' Q4 2023 performance reflects solid financial health and strategic investments for future growth. Despite facing challenges such as rising expenses and competitive pressures, the company is well-positioned to capitalize on opportunities through innovation and market expansion.

Edwards Lifesciences reports robust Q1 sales growth and outlook

Edwards Lifesciences shows strong sales growth across key segments and raises 2024 outlook.
Investments in transcatheter platforms and positive milestones drive sustainable growth.
Challenges include managing increased expenses and ensuring center readiness for new therapies.
Opportunities in AI implementation, patient care initiatives, and diversified growth potential.

Edwards Lifesciences reports strong Q3 performance and strategic growth focus

Edwards Lifesciences delivered robust Q3 results driven by TAVR and TMTT growth, showcasing resilience and innovation.
While facing challenges in certain markets like Japan, Edwards maintains a strong competitive position and strategic focus on long-term growth.
The company's acquisitions, product advancements, and maintained guidance reflect a commitment to expansion and market leadership.
With opportunities in innovation and global expansion, Edwards is poised for continued growth and success in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Apple

Alphabet

Microsoft

Motorola Solutions

Tractor Supply

UnitedHealth Group

Visa

David A. Rolfe is the chief investment officer at Wedgewood Partners and has been managing Wedgewood's portfolio for 18 years.

These Are the Top 10 Holdings of David Rolfe

BOSTON , Sept. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair (TEER) therapies.

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

IRVINE, Calif. , Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR).

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

Edwards Lifesciences' (EW) SAPIEN 3 Ultra RESILIA valve combines its breakthrough RESILIA tissue technology with the SAPIEN 3 Ultra transcatheter aortic heart valve.

Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve

IRVINE, Calif. , Sept. 12, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards' breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve.

EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL

Edwards Lifesciences (EW) expects full-year 2022 underlying sales to grow on the back of strength in demand for products used in more intense surgeries.

Edward Lifesciences (EW) Gains From New Products Amid Cost Woe

OCPNY vs. EW: Which Stock Is the Better Value Option?

OCPNY or EW: Which Is the Better Value Stock Right Now?

Investors do not seem convinced that Edwards Lifesciences Corp. ( EW , Financial) is well equipped to handle a downturn in the medical device industry. Despite what one analyst thinks, the Irving, California-based company has lost 25% of its value this year.

Edwards Lifesciences Best Able to Withstand Medtech Slowdown, Says Analyst

Edwards Lifesciences' (EW) PASCAL Precision system enables precise navigation and implant delivery during mitral and tricuspid regurgitation treatment.

Edwards Lifesciences (EW) Gets CE Mark for PASCAL Precision

IRVINE, Calif. , Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR).

EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK

Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.

Edwards Lifesciences (EW) Q2 Earnings Meet Estimates, Margins Up

Edwards Lifesciences Corporation (NYSE:EW ) Q2 2022 Earnings Conference Call July 28, 2022 5:00 PM ET Company Participants Mark Wilterding - VP, IR and Treasurer Mike Mussallem - Chairman and CEO Scott Ullem - CFO Larry Wood - Global Leader, TAVR Bernard Zovighian - Global Leader, TMTT Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Cecilia Furlong - Morgan Stanley Travis Steed - Bank of America Suraj Kalia - Oppenheimer Ed Ridley - Redburn Bill Plovanic - Canaccord Adam Maeder - Piper Sandler Josh Jennings - Cowen Operator Greetings, and welcome to the Edwards Lifesciences' Second Quarter 2022 Results Conference Call. At this time, all participants are in a listen-only mode.

Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q2 2022 Results - Earnings Call Transcript

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) Matches Q2 Earnings Estimates

Edwards Lifesciences cut its 2022 sales guidance, citing exchange-rate challenges and hospital staffing issues. EW stock tumbled.

Edwards Lifesciences Wipes Out Regular-Session Gains On 2022 Guidance Cut

Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.

Edwards Lifesciences (EW) to Post Q2 Earnings: What's in Store?

IRVINE, Calif. , July 21, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2022 after the market closes on Thursday, July 28, 2022, and will host a conference call at 5:00 p.m.

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 28, 2022

Monster Beverage

Vertex Pharmaceuticals

When screening the market for value opportunities, investors may want to consider stocks that represent companies with high profitability and robust financial conditions. The companies below meet these criteria, as they have GuruFocus profitability and financial strength ratings of at least 6 out of 10.

4 Profitable Companies With Solid Financial Conditions

ABIOMED

The GF Score system from GuruFocus is a unique metric that takes into account a company's financial strength, profitability, growth, valuation and momentum to determine if the stock is likely to outperform. Those stocks with higher GF Scores generally produce higher returns than those with lower GF Scores, according to a backtesting study by GuruFocus.

2 Medical Device Stocks With Extremely High GF Scores

NYON, Switzerland--(BUSINESS WIRE)--Edwards Lifesciences today published ‘Unifying Generations: Building the Pathway to Intergenerational Solidarity' – a report, based on a survey of 12,850 Europeans across generations, that demonstrates the need to change perceptions of the value of people aged over-65 and their cohesion with younger generations. “The European population is ageing. By 2040, 155 million people are expected to be over 651. This demographic change is often referred to as a challe

Edwards Lifesciences' Unifying Generations Report Seeks to Transform Perceptions of the “Pivotal” 3rd Generation

OCPNY vs. EW: Which Stock Should Value Investors Buy Now?

Edwards Lifesciences is well positioned to absorb cost headwinds in the medical technology segment. The company's propensity to drive free cash flow below the bottom line has ensured a robust schedule of growth in earnings and equity value.

Edwards Lifesciences: Seeking 60% Upside For Potential Exit At $160 Per Share

Edwards Lifesciences Corp (NYSE:EW) has taken a tumble in the second quarter, shedding nearly 25% since its mid-April peak near the $131 mark.

Heathcare Stock for Bulls to Watch This June

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock?

Why Is Edwards Lifesciences (EW) Down 11.8% Since Last Earnings Report?

IRVINE, Calif. , May 23, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the Bernstein 38th Annual Strategic Decisions Conference on Thursday, June 2, 2022.

News for Edwards Lifesciences Stock (EW)